ICIs target programmed cell death-1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) on T cells or their ligands, such as programmed cell death 1 ligand-1 (PD-L1) on tumor cells to enhance antitumor T cell activity [8]. Here, CTLA4 is linked to neoplasm.